Floatz logo

Nefopam

Hyperalgesia

University Hospital, BordeauxSmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hyperalgesia cohort.

Asset / SponsorPhaseRating
FENTANYL
University Hospital, Ghent
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Barts & The London NHS Trust
Phase 4BB
Pregabalin
Barts & The London NHS Trust
Phase 4BB
Néfopam
University Hospital, Bordeaux
Phase 2/3B
ROPIVACAINE
University Hospital, Bordeaux
Phase 3B

View all 12 →

Same molecule, other indications

Nefopam is also rated in:

chronic pain syndromeDormant
B
Indicative ·
61 / 100
View asset →
Pain, PostoperativeDormant
B
Indicative ·
58 / 100
View asset →
post-operative pain, non-human animalDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →